Home・Aktien・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Geschlossen

BrancheGesundheitswesen

64.81 0.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

64.31

Max

64.7

Schlüsselkennzahlen
By Trading Economics
Einkommen	638M 3.3B
Verkäufe	1.5B 13B
KGV Branchendurchschnitt	14.421 68.51
EPS	2.04
Dividendenrendite	3.84
Gewinnspanne	25.561
Angestellte	32,500
EBITDA	1.3B 4.9B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+2.44% upside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	3.84% 2.29%
Nächstes Ergebnis	29. Okt. 2026
Nächstes Ex-Dividendendatum	2. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	6B 134B
Vorheriger Eröffnungskurs	64.62
Vorheriger Schlusskurs	64.81

Bristol-Myers Squibb Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Bristol-Myers Squibb Co. Prognose

Kursziel

By TipRanks

2.44% Vorteil

12-Monats-Prognose

Durchschnitt 66.3 USD 2.44%

Hoch 80 USD

Tief 40 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bristol-Myers Squibb Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

21 ratings

Buy

Halten

Sell

Basierend auf 21 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Bristol-Myers Squibb Co. – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.